Analyst Price Targets — JBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 27, 2026 10:14 am | — | H.C. Wainwright | $45.00 | $24.98 | TheFly | Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright |
| March 6, 2026 5:15 pm | Alex Thompson | Stifel Nicolaus | $40.00 | $14.07 | StreetInsider | Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101" |
| January 7, 2026 11:07 am | — | H.C. Wainwright | $25.00 | $13.17 | TheFly | Jade Biosciences initiated with a Buy at H.C. Wainwright |
| October 9, 2025 10:22 am | — | BTIG | $28.00 | $9.08 | TheFly | Jade Biosciences initiated with a Buy at BTIG |
| June 16, 2025 12:17 am | Vamil Divan | Guggenheim | $14.00 | $6.76 | TheFly | Jade Biosciences upgraded to Buy from Neutral at Guggenheim |
| May 5, 2025 8:28 am | Alex Thompson | Stifel Nicolaus | $19.00 | $11.50 | TheFly | Jade Biosciences initiated with a Buy at Stifel |
Latest News for JBIO
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade's Board of Directors granted an equity award to Edward R. Conner, M.D.
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Edward R. Conner, M.D.
SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the fourth quarter and full year ending December 31, 2025, and provided a corporate update.
Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript
SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JBIO.
U.S. House Trading
No House trades found for JBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.